141 Nedenstående tabel angiver de bivirkninger, der er set ved ciprofloxacin i kliniske studier og under overvågning efter markedsføringen (oral, intravenøs og sekventiel behandling).
ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin Bayer (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below.